Corcept Therapeutics (CORT) Income towards Parent Company (2010 - 2026)

Corcept Therapeutics has reported Income towards Parent Company for 17 years, with the latest figure at $43.0 million in Q2 2026.

• Quarterly Income towards Parent Company rose 22.15% year-over-year to $43.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $55.2 million (down 58.7% YoY) and the FY2025 annual result came in at $99.7 million, down 29.43% from the prior year.
• Income towards Parent Company rose to $43.0 million in Q2 2026 per CORT's latest filing, from -$31.7 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $47.2 million in Q3 2024 and troughed at -$31.7 million in Q1 2026.
• A 5-year average of $25.5 million and a median of $27.6 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2026: Income towards Parent Company soared 89.07% in 2023, then sank 254.35% in 2026.
• Over 5 years, Income towards Parent Company stood at $16.6 million in 2022, then surged by 89.07% to $31.4 million in 2023, then declined by 1.96% to $30.8 million in 2024, then declined by 21.08% to $24.3 million in 2025, then surged by 76.99% to $43.0 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered $43.0 million, -$31.7 million, and $24.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.